David Fontana is the Chief Operating Officer at Umoja Biopharma. David joins Umoja from Bristol Myers Squibb, where he was an executive in the Cell Therapy Franchise and part of the Lymphoma Disease Strategy Team. There, he led the development of CD19 CAR T cell therapy BREYANZI® from clinical evaluation to commercialization. Prior to this role, he led the advancement of late-stage immuno-oncology assets and translational medicine as Vice President of Immuno-Oncology at Pfizer. David has successfully guided multiple drug candidates to significant milestones throughout his career, including ADCETRIS® (CD30 antibody-drug conjugate, Brentuximab vedotin), BAVENCIO® (avelumab, anti PD-L1), and relatlimab, (anti-LAG-3 antibody). David received a Ph.D. in Pharmacology from Wayne State University and holds a PMP certification from the Project Management Institute.